106 related articles for article (PubMed ID: 23270928)
1. Selective photodetection and photodynamic therapy for prostate cancer through targeting of proteolytic activity.
Zuluaga MF; Sekkat N; Gabriel D; van den Bergh H; Lange N
Mol Cancer Ther; 2013 Mar; 12(3):306-13. PubMed ID: 23270928
[TBL] [Abstract][Full Text] [Related]
2. Enhanced prostate cancer targeting by modified protease sensitive photosensitizer prodrugs.
Zuluaga MF; Gabriel D; Lange N
Mol Pharm; 2012 Jun; 9(6):1570-9. PubMed ID: 22548315
[TBL] [Abstract][Full Text] [Related]
3. Double-PEGylated Cyclopeptidic Photosensitizer Prodrug Improves Drug Uptake from In Vitro to Hen's Egg Chorioallantoic Membrane Model.
Bouilloux J; Kiening M; Yapi S; Lange N
Molecules; 2021 Oct; 26(20):. PubMed ID: 34684822
[TBL] [Abstract][Full Text] [Related]
4. Thrombin-sensitive dual fluorescence imaging and therapeutic agent for detection and treatment of synovial inflammation in murine rheumatoid arthritis.
Gabriel D; Lange N; Chobaz-Peclat V; Zuluaga MF; Gurny R; van den Bergh H; Busso N
J Control Release; 2012 Oct; 163(2):178-86. PubMed ID: 22959919
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-sensitive photodynamic agents: a novel strategy for selective synovectomy in rheumatoid arthritis.
Gabriel D; Busso N; So A; van den Bergh H; Gurny R; Lange N
J Control Release; 2009 Sep; 138(3):225-34. PubMed ID: 19445983
[TBL] [Abstract][Full Text] [Related]
6. CFTR suppresses tumor progression through miR-193b targeting urokinase plasminogen activator (uPA) in prostate cancer.
Xie C; Jiang XH; Zhang JT; Sun TT; Dong JD; Sanders AJ; Diao RY; Wang Y; Fok KL; Tsang LL; Yu MK; Zhang XH; Chung YW; Ye L; Zhao MY; Guo JH; Xiao ZJ; Lan HY; Ng CF; Lau KM; Cai ZM; Jiang WG; Chan HC
Oncogene; 2013 May; 32(18):2282-91, 2291.e1-7. PubMed ID: 22797075
[TBL] [Abstract][Full Text] [Related]
7. Deregulated expression of urokinase and its inhibitor type 1 in prostate cancer cells: role of epigenetic mechanisms.
Hagelgans A; Menschikowski M; Fuessel S; Nacke B; Arneth BM; Wirth MP; Siegert G
Exp Mol Pathol; 2013 Jun; 94(3):458-65. PubMed ID: 23541763
[TBL] [Abstract][Full Text] [Related]
8. Light-activatable cannabinoid prodrug for combined and target-specific photodynamic and cannabinoid therapy.
Ling X; Zhang S; Liu Y; Bai M
J Biomed Opt; 2018 Oct; 23(10):1-9. PubMed ID: 30334393
[TBL] [Abstract][Full Text] [Related]
9. Tailoring protease-sensitive photodynamic agents to specific disease-associated enzymes.
Gabriel D; Campo MA; Gurny R; Lange N
Bioconjug Chem; 2007; 18(4):1070-7. PubMed ID: 17477499
[TBL] [Abstract][Full Text] [Related]
10. Iterative design of emetine-based prodrug targeting fibroblast activation protein (FAP) and dipeptidyl peptidase IV DPPIV using a tandem enzymatic activation strategy.
Akinboye ES; Brennen WN; Rosen DM; Bakare O; Denmeade SR
Prostate; 2016 Jun; 76(8):703-14. PubMed ID: 26835873
[TBL] [Abstract][Full Text] [Related]
11. Maspin retards cell detachment via a novel interaction with the urokinase-type plasminogen activator/urokinase-type plasminogen activator receptor system.
Yin S; Lockett J; Meng Y; Biliran H; Blouse GE; Li X; Reddy N; Zhao Z; Lin X; Anagli J; Cher ML; Sheng S
Cancer Res; 2006 Apr; 66(8):4173-81. PubMed ID: 16618739
[TBL] [Abstract][Full Text] [Related]
12. Photodynamic therapy with Pd-Bacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts.
Koudinova NV; Pinthus JH; Brandis A; Brenner O; Bendel P; Ramon J; Eshhar Z; Scherz A; Salomon Y
Int J Cancer; 2003 May; 104(6):782-9. PubMed ID: 12640688
[TBL] [Abstract][Full Text] [Related]
13. Targeted prodrug approaches for hormone refractory prostate cancer.
Aloysius H; Hu L
Med Res Rev; 2015 May; 35(3):554-85. PubMed ID: 25529338
[TBL] [Abstract][Full Text] [Related]
14. Quercetin inhibits invasion, migration and signalling molecules involved in cell survival and proliferation of prostate cancer cell line (PC-3).
Senthilkumar K; Arunkumar R; Elumalai P; Sharmila G; Gunadharini DN; Banudevi S; Krishnamoorthy G; Benson CS; Arunakaran J
Cell Biochem Funct; 2011 Mar; 29(2):87-95. PubMed ID: 21308698
[TBL] [Abstract][Full Text] [Related]
15. Pleiotrophic inhibition of pericellular urokinase-type plasminogen activator system by endogenous tumor suppressive maspin.
Biliran H; Sheng S
Cancer Res; 2001 Dec; 61(24):8676-82. PubMed ID: 11751384
[TBL] [Abstract][Full Text] [Related]
16. Iron stimulates urokinase plasminogen activator expression and activates NF-kappa B in human prostate cancer cells.
Ornstein DL; Zacharski LR
Nutr Cancer; 2007; 58(1):115-26. PubMed ID: 17571974
[TBL] [Abstract][Full Text] [Related]
17. Imaging active urokinase plasminogen activator in prostate cancer.
LeBeau AM; Sevillano N; Markham K; Winter MB; Murphy ST; Hostetter DR; West J; Lowman H; Craik CS; VanBrocklin HF
Cancer Res; 2015 Apr; 75(7):1225-35. PubMed ID: 25672980
[TBL] [Abstract][Full Text] [Related]
18. Light-activatable dual-source ROS-responsive prodrug nanoplatform for synergistic chemo-photodynamic therapy.
Yang B; Wang K; Zhang D; Sun B; Ji B; Wei L; Li Z; Wang M; Zhang X; Zhang H; Kan Q; Luo C; Wang Y; He Z; Sun J
Biomater Sci; 2018 Nov; 6(11):2965-2975. PubMed ID: 30255178
[TBL] [Abstract][Full Text] [Related]
19. Cyclopeptidic photosensitizer prodrugs as proteolytically triggered drug delivery systems of pheophorbide A: part I - self-quenched prodrugs.
Bouilloux J; Yushchenko O; Dereka B; Boso G; Zbinden H; Vauthey E; Babič A; Lange N
Photochem Photobiol Sci; 2018 Nov; 17(11):1728-1738. PubMed ID: 30215073
[TBL] [Abstract][Full Text] [Related]
20. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
